The stock of Cue Biopharma Inc (CUE) has gone up by 56.04% for the week, with a 19.66% rise in the past month and a -13.06% drop in the past quarter. The volatility ratio for the week is 20.60%, and the volatility levels for the past 30 days are 12.04% for CUE. The simple moving average for the past 20 days is 27.91% for CUE’s stock, with a -13.48% simple moving average for the past 200 days.
Is It Worth Investing in Cue Biopharma Inc (NASDAQ: CUE) Right Now?
Company’s 36-month beta value is 2.03.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CUE is 47.07M, and currently, short sellers hold a 10.15% ratio of that floaft. The average trading volume of CUE on May 06, 2024 was 281.74K shares.
CUE) stock’s latest price update
The stock price of Cue Biopharma Inc (NASDAQ: CUE) has jumped by 13.30 compared to previous close of 1.88. Despite this, the company has seen a gain of 56.04% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-24 that BOSTON, April 24, 2024 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.
Analysts’ Opinion of CUE
Many brokerage firms have already submitted their reports for CUE stocks, with Jefferies repeating the rating for CUE by listing it as a “Buy.” The predicted price for CUE in the upcoming period, according to Jefferies is $6 based on the research report published on March 13, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CUE reach a price target of $10. The rating they have provided for CUE stocks is “Outperform” according to the report published on June 26th, 2023.
Piper Sandler gave a rating of “Overweight” to CUE, setting the target price at $7 in the report published on November 21st of the previous year.
CUE Trading at 15.43% from the 50-Day Moving Average
After a stumble in the market that brought CUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.40% of loss for the given period.
Volatility was left at 12.04%, however, over the last 30 days, the volatility rate increased by 20.60%, as shares surge +15.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.41% upper at present.
During the last 5 trading sessions, CUE rose by +56.04%, which changed the moving average for the period of 200-days by -52.67% in comparison to the 20-day moving average, which settled at $1.68. In addition, Cue Biopharma Inc saw -19.32% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CUE starting from Suri Anish, who purchase 4,000 shares at the price of $2.76 back on Aug 25 ’23. After this action, Suri Anish now owns 135,638 shares of Cue Biopharma Inc, valued at $11,040 using the latest closing price.
PASSERI DANIEL R, the CHIEF EXECUTIVE OFFICER of Cue Biopharma Inc, purchase 3,000 shares at $2.86 during a trade that took place back on Aug 14 ’23, which means that PASSERI DANIEL R is holding 134,578 shares at $8,580 based on the most recent closing price.
Stock Fundamentals for CUE
Current profitability levels for the company are sitting at:
- -9.47 for the present operating margin
- 0.37 for the gross margin
The net margin for Cue Biopharma Inc stands at -9.26. The total capital return value is set at -1.17. Equity return is now at value -98.73, with -66.40 for asset returns.
Based on Cue Biopharma Inc (CUE), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -3.46. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -37.27.
Currently, EBITDA for the company is -48.56 million with net debt to EBITDA at 0.72. When we switch over and look at the enterprise to sales, we see a ratio of 12.71. The receivables turnover for the company is 3.23for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.01.
Conclusion
In a nutshell, Cue Biopharma Inc (CUE) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
